Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older
Clinical trial NCT02494882 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02494882
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-06-29
- Primary completion
- 2027-06-01
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.